Baudax Bio Announces Closing of $5 Million Public Offering
MALVERN, Pa., Dec. 06, 2022 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for hospital and related settings, today announced the closing of its previously announced public offering of an aggregate of 1,042,787 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-3 warrants to purchase up to 1,042,787 shares of common stock and Series A-4 warrants to purchase 1,042,787 shares of common stock, at a combined public offering price of $4.795 per share (or pre-funded warrant) and accompanying warrants. The Series A-3 warrants have an exercise price of $4.50 per share, are exercisable immediately upon issuance and will expire five years from the date of issuance, and the Series A-4 warrants have an exercise price of $4.50 per share, are exercisable immediately upon issuance and will expire thirteen months from the date of issuance.
Related news for (BXRX)
- Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
- Baudax Bio Reports First Quarter Financial Results and Provides Business Update
- Baudax Bio Reports First Quarter Financial Results and Provides Business Update
- Baudax Bio Announces Pricing of $4 Million Public Offering
- Baudax Bio Announces Pricing of $4 Million Public Offering